Stephens & Co. Maintains Equal-Weight on DermTech, Lowers Price Target to $1.5
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Mason Carrico maintains an Equal-Weight rating on DermTech (NASDAQ:DMTK) and lowers the price target from $2.5 to $1.5.
March 05, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stephens & Co. maintains an Equal-Weight rating on DermTech and lowers the price target from $2.5 to $1.5.
The reduction in price target by Stephens & Co. suggests a bearish outlook on DermTech's stock value in the short term, potentially leading to a decrease in investor confidence and a downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100